Bevacizumab reduces PD-L1 Not PD-1 inhibitor-associated pneumonitis in non-small cell lung cancer patients
Our study showed that bevacizumab was associated with a higher reported proportion of PD-1 inhibitor-associated IP but a lower reported proportion of PD-L1 inhibitor-associated IP. Although this was a post-marketing, observational study with many limitations, bevacizumab might be a proper combination with PD-L1 inhibitors in consideration of IP, especially in patients at high risk of IP. However, this relationship still needs further clinical validation.
Authors
- Lucheng Zhu (ORCID: https://orcid.org/0000-0001-7298-4166)
- Bing Xia (ORCID: https://orcid.org/0000-0003-3259-6139)
- Yasi Xu (ORCID: https://orcid.org/0000-0003-1806-6545)
- Linling Wang (ORCID: https://orcid.org/0000-0003-1092-0073)
- Yanyan Zhao (ORCID: https://orcid.org/0000-0001-9865-2741)
Institutions
- Zhejiang Chinese Medical University (CN)
- Affiliated Hangzhou First People's Hospital, Westlake University, School of Medicine (CN)
- Hangzhou Cancer Hospital (CN)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-10-10
- DOI
- https://doi.org/10.1007/s00262-025-04158-1
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05